Corient Private Wealth
CGTX icon

Corient Private Wealth’s Cognition Therapeutics CGTX Stock Holding History

Corient Private Wealth’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90K Buy
78,226
+6,114
+8% +$7.24K ﹤0.01% 2948
2026
Q1 		$54.8K Hold
72,112
– – ﹤0.01% 2752
2025
Q4 		$97.4K Hold
72,112
– – ﹤0.01% 2554
2025
Q3 		$97.4K Buy
+72,112
New +$98.3K ﹤0.01% 2452

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Corient Private Wealth's CGTX Position: Q2 2026 in Review

Corient Private Wealth increased its Cognition Therapeutics (CGTX) stake by 8.5% in Q2 2026, buying an estimated $7.24K and bringing the position to 78,226 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #2948.

Corient Private Wealth first reported a position in CGTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $97.4K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Corient Private Wealth held 78,226 shares of Cognition Therapeutics worth $90K as of Q2 2026.
  • Corient Private Wealth bought 6,114 Cognition Therapeutics shares in Q2 2026, an estimated $7.24K.
  • Cognition Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2948 holding.
  • Corient Private Wealth first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Corient Private Wealth's Cognition Therapeutics position peaked at $97.4K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.